Reference

Oral miltefosine for the treatment of Indian visceral leishmaniasis

All Rights Reserved. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Sundar, Shyam; Jha, T. K.; Thakur, C. P.; Bhattacharya, S.Some commonly used reagents like 58066-85-6 and 1397-89-3 are used in this experiment. K.; Rai, M. ( Kala-azar Research Center, Banaras Hindu University, Varanasi, India). Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(Suppl. 1), S26-S33 (English) 2006 Elsevier Ltd. CODEN: TRSTAZ. ISSN: 0035-9203. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Large-scale antimony resistance in the treatment of visceral leishmaniasis (VL) in north Bihar, India, has led to the development of miltefosine as an alternative therapy. In a pilot study and later in three Phase II studies involving 249 patients, oral miltefosine, 100-150 mg/day for 28 days, was shown to cure ~90% patients with reasonable safety. In the pivotal Phase III trial, 299 patients were treated at three centers with amphotericin B as the comparator drug (99 patients). In this trial 38% and 20% patients had mild to moderate vomiting and diarrhea resp., similar to previous studies. Asymptomatic transient elevation of hepatic transaminases and mild renal dysfunction were obsd. in 15% and 10% patients resp. The final cure rate was 94% with miltefosine and 97% with amphotericin B; based on these results, the drug was approved in India. Subsequently in two pediatric studies involving 119 patients in the age group of 2-11 years, the safety and efficacy of miltefosine (2.5 mg/kg daily for 28 days) was established with a cure rate (94%) similar to that seen in adults. Miltefosine is the first oral antileishmanial drug with a high degree of safety and efficacy for the treatment of VL. .

Miltefosine: issues to be addressed in the future

All Rights Reserved. Miltefosine: issues to be addressed in the future. Berman, J.; Bryceson, A. D. M.; Croft, S.; Engel, J.; Gutteridge, W.; Karbwang, J.; Sindermann, H.; Soto, J.; Sundar, S.; Urbina, J. A. ( Rockville, MD 20852, USA). Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(Suppl. 1), S41-S44 (English) 2006 Elsevier Ltd. CODEN: TRSTAZ. ISSN: 0035-9203. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clin.In this experiment, several chemicals are used like 58066-85-6 practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clin. conditions. .